$98.51
▲ +0.1% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Veradermics to Present at Upcoming September Investor Conferences
Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
Overview
52-week range
$32
$131
67% of range
Avg surprise (last 1)
-135.7%
Avg reaction (last 1)
-3.9%
0% positive
Latest IV / EM
109%
EM ±17.0% · $100 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.58 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-1.32 | $-0.56 | -135.7% | — | -3.9% | earnings |
| Mon Jun 30, 2025 | Jun 2025 | $-24.19 | — | — | — | — | financials |
| Mon Mar 31, 2025 | Mar 2025 | $-19.79 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-30M | $-30M | — | $-16M | $-13M |
| Net income | $-24M | $-27M | — | $-16M | $-12M |
| EPS (diluted) | $-0.58 | $-1.32 | — | $-24.19 | $-19.79 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $319M | $168M | $22M | — | — |
| Inventory | — | — | — | — | — |
| Total current assets | $825M | $397M | $152M | — | — |
| Total assets | $826M | $397M | $153M | — | — |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $12M | $7M | $9M | — | — |
| Total equity | $814M | $391M | $-121M | $-76M | $-61M |